Since the approval of the first monoclonal antibody (mAb), rituximab, for hematological malignancies, almost 30 additional mAbs have been approved in oncology. Despite remarkable advances, relatively weak responses and resistance to antibody monotherapy remain major open issue. Overcoming resistance might require combinations of drugs blocking both the major target and the emerging secondary target. We review clinically approved combinations of antibodies and either cytotoxic regimens (chemotherapy and irradiation) or kinase inhibitors. Thereafter, we focus on the most promising and currently very active arena that combines mAbs inhibiting immune checkpoints or growth factor receptors. Clinically approved and experimental oligoclonal mixtures of mAbs targeting different antigens (hetero-combinations) or different epitopes of the same antigen (homo-combinations) are described. Effective oligoclonal mixtures of antibodies that mimic the polyclonal immune response will likely become a mainstay of cancer therapy.

Marrocco, I., Romaniello, D., Yarden, Y., Cancer Immunotherapy: The Dawn of Antibody Cocktails, in Steinitz, M. (ed.), Human Monoclonal Antibodies, Humana Press, New York 2019: <<METHODS IN MOLECULAR BIOLOGY>>, 1904 11- 51. 10.1007/978-1-4939-8958-4_2 [https://hdl.handle.net/10807/227227]

Cancer Immunotherapy: The Dawn of Antibody Cocktails

Marrocco, Ilaria
Primo
;
2019

Abstract

Since the approval of the first monoclonal antibody (mAb), rituximab, for hematological malignancies, almost 30 additional mAbs have been approved in oncology. Despite remarkable advances, relatively weak responses and resistance to antibody monotherapy remain major open issue. Overcoming resistance might require combinations of drugs blocking both the major target and the emerging secondary target. We review clinically approved combinations of antibodies and either cytotoxic regimens (chemotherapy and irradiation) or kinase inhibitors. Thereafter, we focus on the most promising and currently very active arena that combines mAbs inhibiting immune checkpoints or growth factor receptors. Clinically approved and experimental oligoclonal mixtures of mAbs targeting different antigens (hetero-combinations) or different epitopes of the same antigen (homo-combinations) are described. Effective oligoclonal mixtures of antibodies that mimic the polyclonal immune response will likely become a mainstay of cancer therapy.
2019
Inglese
Human Monoclonal Antibodies
978-1-4939-8957-7
Humana Press
1904
Marrocco, I., Romaniello, D., Yarden, Y., Cancer Immunotherapy: The Dawn of Antibody Cocktails, in Steinitz, M. (ed.), Human Monoclonal Antibodies, Humana Press, New York 2019: <<METHODS IN MOLECULAR BIOLOGY>>, 1904 11- 51. 10.1007/978-1-4939-8958-4_2 [https://hdl.handle.net/10807/227227]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/227227
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? ND
social impact